Aleksey Novikov
Clinical Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Aleksey Novikov is a Clinical Assistant Professor at the University of Florida, specializing in advanced endoscopic procedures and interventions. His research interests include the comparative efficacy of various endoscopic techniques, the management of pancreatic collections, and the analysis of surgical outcomes. Recent articles authored by Dr. Novikov explore topics such as the efficacy of different approaches to treating gastrointestinal neoplasia and the risk factors associated with endoscopic procedures. He is dedicated to improving patient outcomes through innovative research in the field of gastroenterology.
Articles (13)
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Background and Aims Obesity is a risk factor for relapsing inflammatory bowel disease. GLP-1 and dual GLP-1/GIP agonists may offer superior weight loss; however, their effect on inflammatory bowel disease remains unknown. In this study, we assessed outcomes in patients with IBD and obesity using these medications. Methods A retrospective, propensity-matched analysis was conducted using data from The OneFlorida+ network. We evaluated patients with IBD and obesity prescribed GLP-1-based therapy (liraglutide, semaglutide, or tirzepatide) versus those without. 562 patients prescribed GLP-1-based therapies were matched 1:1 to controls based on demographics and comorbidities. Results No differences in GLP-1 users versus non-users with respect to all-cause hospitalization, IBD-hospitalization, IBD-related surgery, or pancreatitis were seen. Use of semaglutide reduced the risk of IBD-related surgery (HR 0.33, CI 0.13-0.83). Among 89 tirzepatide users, none required IBD-related surgery versus 2 matched controls. Black GLP-1 users had an increased risk of all-cause hospitalizations (HR 1.59, CI 1.11–2.29) but not IBD-related hospitalization or IBD-related surgery. Steroid use was comparable between groups. GLP-1 use significantly reduced serum CRP. Conclusions Semaglutide appeared to lower the risk of IBD-related surgery. Black patients using GLP-1 therapy had an increased risk of all-cause hospitalization. Tirzepatide showed no significant difference regarding primary endpoints; however, the sample size was small. Overall, all GLP-1-based therapies were well tolerated among obese patients with IBD. Larger studies are warranted to understand the therapeutic potential of GLP-1-based treatment in this patient population. Graphical Abstract
Year:
2025
Year:
2024
Year:
2023
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Collaborators (7)
Monica Gaidhane
Associate Professor of Research
-
Hao Dai
University of Florida Health
ilyas sahin
Massachusetts General Hospital
Jingchuan Guo
-
Thomas J George
University of Florida
Kunzah Syed
Clinical Assistant Professor at the Heritage College of Osteopathic Medicine
Ohio University
Jiang Bian
Professor and Vice Chair of Translational Informatics
Indiana University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.